Health Canada
www.hc-sc.gc.ca
Common menu bar links
Institutional links
About Health Canada
Access to Information Requests Completed - June 2014
The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)
If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.
| Request # | Summary of Requests | Status of Completed Request | Number of Pages Disclosed |
|---|---|---|---|
| A-2011-01012 | All records related to Colgate Toothbrush Recall. (Apr 1, 2011 to Nov 4, 2011). | Disclosed in part | 478 |
| A-2012-00827 | Summaries, assessments and analyses of media coverage of Nutrition North Canada. (May 1, 2010 to Aug 10, 2012). | Disclosed in part | 549 |
| A-2012-01027 | Documents relating to the article entitled "Noise Annoyance in Canada" (Noise Health. 2005 Apr-Jun;7(27):39-47). | Disclosed in part | 121 |
| A-2012-01616 | Adverse Reaction Report (AER) for Zyprexa. Report numbers: 000376048, 000377471, 000379019, 000383492, 000384744, 000384935, 000388776, 000392050, 000396093, 000411415. | Disclosed in part | 34 |
| A-2013-00573 | Information regarding the medical device LUTONIX 014 DRUG COATED PTA DILATATION CATHETER, License number 91277. | Disclosed in part | 42 |
| A-2013-00797 | Documents regarding whether or not any compassion club in Canada has been authorized by the Minister of Health for any purpose connected to marihuana (such as through an exemption under section56 of the Controlled Drugs and Substances Act). (Jan 1, 1950 to Oct 8, 2013). | Disclosed in part | 171 |
| A-2013-00965 | Adverse Reaction Report (AER) for Buckley's. Report numbers: 000184729, 000216498, 000221169, 000221175, 000221310, 000226624, 000305080, 000314604, 000319304, 000327226, 000331758, 000335989, 000338272, 000339230. | Disclosed in part | 63 |
| A-2013-00972 | Periodic safety update reports filed by McNeil Consumer Healthcare Canada/Johnson and Johnson for all acetaminophen-based products. (Jan 1, 2008 to Nov 13, 2013). | No records exist | 0 |
| A-2013-00987 | Documents between Health Canada and an applicant for a Class II Medical Device Licence containing supporting arguments made by either side for disputed applications. | Disclosed in part | 41 |
| A-2013-01071 | Information regarding Policosanol 10 Mg, Natural Product Number (NPN) 80003259 by SISU Inc. | Disclosed in part | 279 |
| A-2013-01096 | Information regarding the medical device Laser System, License number 70338 by OMEGA LASER SYSTEMS LIMITED. | Disclosed in part | 357 |
| A-2013-01137 | Copies of Module 1, 2 and 3 of the New Drug Submission for Miconazole Nitrate submission number 09059. | All exempted | 0 |
| A-2013-01234 | Clinical trials used to approve Yasmin 21 and Yasmin 28, Drug Identification Number (DIN) 02261723 and 02261731. | No records exist | 0 |
| A-2013-01327 | Information regarding Lymphazurin 1% (Isosulfan Blue), Drug Identification Number (DIN) 00592358. | Disclosed in part | 142 |
| A-2013-01398 | Documents regarding the role of physicians in the new medical marihuana regime taking effect April 1, 2014. (Jan. 1, 2011 to Feb 26, 2014). | Disclosed in part | 181 |
| A-2013-01430 | Reports and/or advice to Natural Resources Canada regarding the Talbot Windfarm / Spence Windfarm, Ontario. (Jan 1, 2003 to Mar 10, 2014). | Disclosed in part | 37 |
| A-2013-01436 | Draft Memorandum of Understanding between Health Canada (HC) and the National Research Council on HC's Collection and amalgamating library services | Disclosed in part | 5 |
| A-2013-01442 | Letter issued prior to March 15, 2006 from Therapeutic Products Directorate to Laboratoire Riva Inc. certifying that the examination of Riva Azithromycin (Azithromycin Monohydrate) 250 mg tablets was complete. | Disclosed in part | 1 |
| A-2013-01443 | Letter issued prior to November 1, 2005 from Therapeutic Products Directorate to Cobalt Pharmaceuticals Inc. certifying that the examination of Co Azithromycin (Azithromycin Monohydrate) 250 mg tablets was complete. | Disclosed in part | 1 |
| A-2013-01445 | Letter issued prior to November 4, 2005 from Therapeutic Products Directorate to Novopharm Limited certifying that the examination of Novo-Azithromycin (Azithromycin Monohydrate Hemiethanolate) 250 mg tablets was complete. | Disclosed in part | 2 |
| A-2013-01448 | Letter issued prior to May 1, 2009 from Therapeutic Products Directorate to Genpharm Inc. certifying that the examination of Gen-Azithromycin (Azithromycin Monohydrate Hemiethanolate) 250 mg tablets was complete. | Disclosed in part | 1 |
| A-2013-01470 | Letter issued prior to November 08, 2012 from Therapeutic Products Directorate to Mint Pharmaceuticals Inc. certifying that the examination of MINT-Sildenafil (Sildenafil Citrate) 25, 50 and 100 mg tablets was complete. | Disclosed in part | 2 |
| A-2013-01471 | Letter issued prior to November 08, 2012 from Therapeutic Products Directorate to Apotex Incorporated certifying that the examination of APO-Sildenafil (Sildenafil Citrate) 25, 50 and 100 mg tablets was complete. | Disclosed in part | 2 |
| A-2013-01472 | Letter issued prior to November 08, 2012 from Therapeutic Products Directorate to Cobalt Pharmaceuticals Company certifying that the examination of Co Sildenafil (Sildenafil Citrate) 25, 50 and 100 mg tablets was complete. | Disclosed in part | 2 |
| A-2013-01475 | Letter issued prior to November 08, 2012 from Therapeutic Products Directorate to Mylan Pharmaceuticals ULC certifying that the examination of Mylan-Sildenafil (Sildenafil Citrate) 25, 50 and 100 mg tablets was complete. | Disclosed in part | 2 |
| A-2013-01476 | Letter issued prior to December 18, 2012 from Therapeutic Products Directorate to Teva Canada Limited certifying that the examination of Ratio-Sildenafil was complete. | Disclosed in part | 1 |
| A-2013-01486 | Adverse Reaction Report (AER) for Fludara. Report numbers: E2B_00013112, 000516319. | Disclosed in part | 137 |
| A-2013-01508 | Reports and/or advice to Natural Resources Canada regarding the Talbot Wind Project located in Chatham-Kent, Ontario. (Jan 1, 2003 to Mar 18, 2014). | Disclosed in part | 37 |
| A-2013-01524 | Documents in regards to K2, K2wind, K2 wind Ontario,K2 wind Ltd or any of its parent companies relating to their K2 (Kingsbridge 2) wind farm development. (Jan 1, 2003 to Mar 31, 2014). | Disclosed in part | 53 |
| A-2013-01530 | Adverse Reaction Reports (AER) for Cyklokapron (tranexamic acid) 500 mg. | Disclosed in part | 10 |
| A-2013-01546 | Documents related to consultations conducted between Health Canada officials and public health stakeholders specific to electronic cigarettes. (Sep 1, 2013 to Mar 15, 2014). | Disclosed in part | 58 |
| A-2013-01549 | Exit Notice Report relating to the inspection of Laboratory Matrix located in St-Laurent, Québec. | Disclosed in part | 9 |
| A-2014-00010 | Letter issued prior to March 07, 2014 from Therapeutic Products Directorate to Mint Pharmaceuticals Inc. certifying that the examination of Mint-Latanoprost (Latanoprost) was complete. | Disclosed in part | 2 |
| A-2014-00017 | Letter issued prior to August 25, 2011 from Therapeutic Products Directorate to Cobalt Pharmaceuticals Company certifying that the examination of Co Latanoprost (Latanoprost) was complete. | Disclosed in part | 2 |
| A-2014-00019 | Letter issued prior to December, 6, 2011 from Therapeutic Products Directorate to Sandoz Canada Incorporated certifying that the examination of Sandoz Latanoprost (Latanoprost) was complete. | Disclosed in part | 2 |
| A-2014-00051 | Adverse Reaction Report (AER). Report numbers: 000550077, 000544295, 000544786, 000544308, 000544256. | Disclosed in part | 25 |
| A-2014-00108 | Adverse Reaction Report (AER) for TECTA. Report numbers: 000489695, 000491487, 000499703, 000500722, 000501495, 000503220, 000507946, 000508653, 000509303, 000509435, 000513472, 000513091. | Disclosed in part | 23 |
| A-2014-00110 | Adverse Reaction Report (AER) for Humalog. Report numbers: 000561004, 000576604. | Disclosed in part | 3 |
| A-2014-00129 | Adverse Reaction Report (AER). Report numbers: 000516632, 000524436, 000524561, 000532962, 000533928, 000534316, 000537601, 000537638, 000538820, 000540169, 000540865. | Disclosed in part | 18 |
| A-2014-00133 | Adverse Reaction Report (AER) for ONDANSETRON. Report numbers: 000557076, 000502601, E2B_00021481. | Disclosed in part | 10 |
| A-2014-00159 | Information regarding Sovaldi (Sofosbuvir), Drug Identification Number (DIN) 02418355 by Gilead Sciences Canada Inc. | All disclosed | 1 |
| A-2014-00160 | Adverse Reaction Report (AER) for Calcium Folinate. Report numbers: 000543144, 000541619. | Disclosed in part | 16 |
| A-2014-00166 | Documents regarding the Medical Marihuana Access Program application pertaining to facility Standard Operating Procedures and Threat Risk Assessment or Vulernabilty Evaluation completed on Phytotron's proposed site located in Osoyoos, British Columbia | No records exist | 0 |
| A-2014-00178 | All registries and/or lists of marihuana grow operations in Canada operating. (Jan.1, 2010 to May 15, 2014). | No records exist | 0 |
| A-2014-00180 | All contracts awarded through the ProServices procurement system for services provided within the National Capital Region. (Jan 1, 2013 to Feb 28, 2014). | All disclosed | 2 |
| A-2014-00181 | All contracts awarded via the Temporary Help System (THS) and Task Based Informatics Professional Services (TBIPS), to the companies Excel HR and (Altis HR or Altis Professional) for services provided within the National Capital Region.(Jan 1, 2013 to Feb 28, 2014) | Disclosed in part | 314 |
| A-2014-00189 | Documents to verify whether executives or public servants have asked telecommunication companies or firms for personal data on their Canadian subscribers abroad. (Jan. 1, 2011 to Dec. 31, 2013). | No records exist | 0 |
| A-2014-00192 | Adverse Reaction Report (AER) for Taxotere. Report number: 000563878. | Disclosed in part | 2 |
| A-2014-00195 | Adverse Reaction Report (AER) for Taxotere. Report number: E2B_00033829. | Disclosed in part | 141 |
| A-2014-00198 | Adverse Reaction Report (AER) for Lovenox. Report number: 000573200. | Disclosed in part | 4 |
| A-2014-00199 | Adverse Reaction Report (AER) for Lovenox. Report number: 000573078. | Disclosed in part | 4 |
| A-2014-00208 | Documents pertaining to the number of licences granted for medical marihuana grow operations. (Jun 14, 2001 to Mar 20, 2014). | Disclosed in part | 45 |
| A-2014-00210 | Documents pertaining to the number of licences granted for medical marihuana grow operations. (Mar 21, 2014 to May 6, 2014). | All disclosed | 1 |
| A-2014-00213 | Adverse Reaction Report (AER). Report numbers: 000572262, 000572564, 000574048, 000559518, 000560643. | Disclosed in part | 10 |
| A-2014-00218 | Copy of all statistics or other data detailing the number of phone calls received by the police force to verify certain information, does a suspicious individual really hold a valid medical marihuana grow operation license. (Jan 1, 2001 to May 13, 2014). | All disclosed | 1 |
| A-2014-00219 | Adverse Reaction Report (AER). Report number: 000563175. | Disclosed in part | 1 |
| A-2014-00235 | Adverse Reaction Report (AER). Report numbers: 000575425, 000558500, 000565203. | Disclosed in part | 5 |
| A-2014-00241 | Adverse Reaction Report (AER) for Androgel. Report number: 000571878. | Disclosed in part | 1 |
| A-2014-00242 | Adverse Reaction Report (AER) for Luvox. Report numbers: 000558815, 000564876. | Disclosed in part | 3 |
| A-2014-00243 | Adverse Reaction Report (AER) for Mavik. Report number: 000569102. | Disclosed in part | 1 |
| A-2014-00244 | Adverse Reaction Report (AER) for Biaxin. Report number: 000568333. | Disclosed in part | 2 |
| A-2014-00250 | Adverse Reaction Report (AER). Report number: 000578755. | Disclosed in part | 5 |
| A-2014-00252 | Copies of all investigative reports and other data which have led to sanctions for inappropriate use of computer equipment. (Jan. 1, 2011 to May 16, 2014). | Disclosed in part | 147 |
| A-2014-00256 | All briefing notes for the Minister regarding neonicotinoids. (Jan 1, 2013 to May 22, 2014). | All disclosed | 12 |
| A-2014-00259 | Adverse Reaction Report (AER) for MICARDIS. Report number: 000476872. | Disclosed in part | 1 |
| A-2014-00262 | Adverse Reaction Report (AER) for Eloxatin. Report number: E2B_00031944. | All disclosed | 12 |
| A-2014-00263 | Adverse Reaction Report (AER) for Eloxatin. Report number: 000562244. | Disclosed in part | 2 |
| A-2014-00264 | Adverse Reaction Report (AER) for Eloxatin. Report number: 000562554. | Disclosed in part | 1 |
| A-2014-00266 | Adverse Reaction Report (AER) for Eloxatin. Report number: 000559391. | Disclosed in part | 2 |
| A-2014-00269 | Adverse Reaction Report (AER) for Aerius. Report numbers: 000502569, 000457900, 000457899, 000455116, 000437349, 000396782, 000381586, 000509337. | Disclosed in part | 11 |
| A-2014-00271 | Adverse Reaction Report (AER) for Gliclazide. Report numbers: 000338972, 000470372. | Disclosed in part | 2 |
| A-2014-00278 | Adverse Reaction Report (AER) for Andriol. Report number: 000453816. | Disclosed in part | 2 |
| A-2014-00279 | Adverse Reaction Report (AER) for Claritin. Report numbers: 000484380, 000435891, 000436346, 000445329. | Disclosed in part | 4 |
| A-2014-00280 | Adverse Reaction Report (AER) for Coricidin. Report numbers: 000380855, 000384262. | Disclosed in part | 2 |
| A-2014-00281 | Adverse Reaction Report (AER) for Cosopt. Report numbers: 000400679, 000432632. | Disclosed in part | 2 |
| A-2014-00282 | Adverse Reaction Report (AER) for Cotazym. Report number: 000380802. | Disclosed in part | 1 |
| A-2014-00283 | Adverse Reaction Report (AER) for Cozaar. Report numbers: 000468873, 000452200, 000435226, 000406321. | Disclosed in part | 5 |
| A-2014-00284 | Adverse Reaction Report (AER) for Elocom. Report number: 000441953. | Disclosed in part | 3 |
| A-2014-00287 | Briefing notes to the Minister about the increase of bariatric surgeries, including associated risks and costs. (Jan 1 2014 to May 30, 2014). | No records exist | 0 |
| A-2014-00289 | Briefing notes to the Minister, risk analysis and communications plans/strategies, around the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). (Mar 1, 2014 to May 30, 2014). | Disclosed in part | 10 |
| A-2014-00312 | Adverse Reaction Report (AER) for Emend. Report number: 000465569. | Disclosed in part | 2 |
| A-2014-00313 | Adverse Reaction Report (AER) for Estrogel. Report numbers: 000409456, 000428520, 000473903, 000476911, 000491375. | Disclosed in part | 7 |
| A-2014-00316 | Adverse Reaction Report (AER) for Ezetrol. Report numbers: 000474638, 000474017, 000472824, 000469358, 000461853, 000410977, 000407867, 000484378. | Disclosed in part | 11 |
| A-2014-00317 | Adverse Reaction Report (AER) for Fosamax. Report numbers: 000483569, 000474596, 000456212, 000439509, 000510846, 000505486, 000401852, 000492827, 000488487, 000484217, 000482362, 000479096, 000477658, 000477645, 000470208, 000469849, 000462803, 000451204, 000450146, 000442362, 000435253, 000426118, 000410189, 000403800. | Disclosed in part | 41 |
| A-2014-00318 | Adverse Reaction Report (AER) for Fosavance. Report numbers: 000505489, 000468253, 000434992, 000432276, 000429485, 000429188, 000424380, 000419203, 000415204, 000422297, 000439948, 000442292, 000463888, 000474655, 000493347. | Disclosed in part | 27 |
| A-2014-00319 | Adverse Reaction Report (AER) for Garamycin. Report numbers: 000446217, 000435862. | Disclosed in part | 2 |
| A-2014-00320 | Adverse Reaction Report (AER) for Garasone. Report number: 000413953. | Disclosed in part | 2 |
| A-2014-00321 | Adverse Reaction Report (AER) for Gardasil. Report numbers: 000509301, 000411615, 000438175, 000445637, 000457935, 000496867, 000504294, 000504081, 000484024, 000460512, 000457789, 000449128, 000448900, 000439568, 000433158, 000410120. | Disclosed in part | 57 |
| A-2014-00322 | Adverse Reaction Report (AER) for Hyzaar/DS. Report numbers: 000408940, 000467469, 000455952. | Disclosed in part | 4 |
| A-2014-00324 | Adverse Reaction Report (AER) for Invanz. Report numbers: 000441377, 000453183, 000484860, 000498991. | Disclosed in part | 6 |
| A-2014-00325 | Adverse Reaction Report (AER) for Janumet. Report numbers: 000502785, 000500415, 000467393, 000505375, 000503615, 000489162, 000485701, 000459996, 000455861. | Disclosed in part | 11 |
| A-2014-00351 | Documents relating to: Authorizing the transfer of marihuana or cannabis from a Marihuana Medical Access Regulations (MMAR) licensee to a Marihuana for Medical Purposes Regulations (MMPR) licensee on or after April 1, 2014. | No records exist | 0 |
